BR0009814A - Processo para tratar de uma doença associada com o receptor-beta estrogênico - Google Patents

Processo para tratar de uma doença associada com o receptor-beta estrogênico

Info

Publication number
BR0009814A
BR0009814A BR0009814-0A BR0009814A BR0009814A BR 0009814 A BR0009814 A BR 0009814A BR 0009814 A BR0009814 A BR 0009814A BR 0009814 A BR0009814 A BR 0009814A
Authority
BR
Brazil
Prior art keywords
receptor
disease associated
treating
estrogen beta
estrogen
Prior art date
Application number
BR0009814-0A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Timothy Martin Piser
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0009814A publication Critical patent/BR0009814A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"PROCESSO PARA TRATAR DE UMA DOENçA ASSOCIADA COM O RECEPTOR-BETA ESTROGêNICO". Um processo para tratar de uma doença associada com o receptor-<225> estrogênico, compreendendo a etapa de administrar uma quantidade terapeuticamente eficaz de um composto que satisfaça a equação: (Ki<244>A/Ki<244>A)/(Ki<244>E/Ki<244>E) > 1, opcionalmente tendo a estrutura geral (I)
BR0009814-0A 1999-04-16 2000-04-11 Processo para tratar de uma doença associada com o receptor-beta estrogênico BR0009814A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12990199P 1999-04-16 1999-04-16
PCT/GB2000/001380 WO2000062765A2 (en) 1999-04-16 2000-04-11 ESTROGEN RECEPTOR-β LIGANDS

Publications (1)

Publication Number Publication Date
BR0009814A true BR0009814A (pt) 2002-01-08

Family

ID=22442124

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009814-0A BR0009814A (pt) 1999-04-16 2000-04-11 Processo para tratar de uma doença associada com o receptor-beta estrogênico

Country Status (22)

Country Link
US (1) US6518301B1 (pt)
EP (1) EP1173164A2 (pt)
JP (1) JP2002542187A (pt)
KR (1) KR20010108509A (pt)
CN (1) CN1358091A (pt)
AR (1) AR043085A1 (pt)
AU (1) AU4128800A (pt)
BG (1) BG106103A (pt)
BR (1) BR0009814A (pt)
CA (1) CA2370126A1 (pt)
CZ (1) CZ20013714A3 (pt)
EE (1) EE200100526A (pt)
HU (1) HUP0200740A3 (pt)
IL (1) IL145839A0 (pt)
IS (1) IS6108A (pt)
MX (1) MXPA01010423A (pt)
NO (1) NO20015015L (pt)
PL (1) PL351314A1 (pt)
SK (1) SK14762001A3 (pt)
TR (2) TR200102992T2 (pt)
WO (1) WO2000062765A2 (pt)
ZA (1) ZA200108409B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AU2001296119A1 (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Estrogen receptor-beta ligands
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
JP2004515494A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
US6559177B2 (en) 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
DK1448544T3 (da) 2001-11-19 2007-10-08 Lilly Co Eli Substituerede benzopyraner som selektive estrogenreceptor-beta-agonister
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7235539B2 (en) 2002-01-23 2007-06-26 Wyeth 6-Hydroxyequilenins as estrogenic agents
WO2003074044A1 (en) * 2002-03-01 2003-09-12 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2004009035A2 (en) 2002-07-24 2004-01-29 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
AU2003255232A1 (en) * 2002-08-07 2004-02-25 University Of Mississippi Antigiardial agents and use thereof
US8580846B2 (en) * 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
EP1626974B1 (en) 2003-04-21 2008-08-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1740191A4 (en) * 2004-04-28 2008-07-30 Univ Brigham Young USE OF EQUOL FOR THE TREATMENT OF SKIN DISEASES
WO2006026316A2 (en) * 2004-08-26 2006-03-09 Wyeth Prodrug substituted benzoxazoles as estrogenic agents
RU2007106870A (ru) 2004-09-07 2008-10-20 Вайет (Us) 6Н-[1]БЕНЗОПИРАНО[4,3-b]ХИНОЛИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЭСТРОГЕННЫХ АГЕНТОВ
WO2006065968A2 (en) * 2004-12-17 2006-06-22 Wyeth The uses of estrogen beta agonists to treat cognitive diseases
WO2006088716A1 (en) * 2005-02-15 2006-08-24 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
EP2526941A1 (en) * 2005-03-24 2012-11-28 Marshall Edwards, Inc. Anti-inflammatory Modalities
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
EP2455362A1 (en) * 2005-11-28 2012-05-23 GTX, Inc. Nuclear receptor binding agents
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
EP2340292B1 (de) * 2008-10-29 2013-05-29 Merck Patent GmbH Flüssigkristallanzeige
TWI492943B (zh) 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）
ES2343347B2 (es) * 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CN101863867B (zh) * 2009-04-14 2012-07-18 清华大学深圳研究生院 黄酮类化合物的衍生物及其制备方法与应用
WO2012147102A1 (en) * 2011-04-25 2012-11-01 Council Of Scientific & Industrial Research Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders
CN103450134B (zh) * 2012-05-31 2017-12-22 中国医学科学院药物研究所 香豆素衍生物的制备及其在防治脑部重大疾病中的应用
US9718799B2 (en) 2015-05-11 2017-08-01 University Of Kentucky Research Foundation 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer
EP3597187A1 (en) * 2018-07-16 2020-01-22 Centre National De La Recherche Scientifique Brag2 inhibitors and applications thereof
CN112574177B (zh) * 2020-12-21 2023-01-31 陕西师范大学 一类嘧啶衍生物及其制备抗肿瘤药物的应用
CN115322198A (zh) * 2022-06-13 2022-11-11 上海工程技术大学 基于喹诺里西啶类衍生物的药物化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954371A (pt) * 1972-09-28 1974-05-27
GB1495189A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 4-oxo-4h-benzopyran derivatives and process for their preparation
JPS6048924A (ja) * 1983-08-24 1985-03-16 Takeda Chem Ind Ltd 骨粗鬆症治療剤
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
JP3085464B2 (ja) * 1990-05-24 2000-09-11 コニカ株式会社 感熱拡散転写材料
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
JPH05112552A (ja) * 1991-10-17 1993-05-07 Tanabe Seiyaku Co Ltd ベンゾピラン誘導体及びその製法
JP3166093B2 (ja) * 1993-08-13 2001-05-14 森永乳業株式会社 クマリン誘導体及びそれらの用途
JPH06321752A (ja) * 1993-05-07 1994-11-22 Kao Corp 美白剤
JP3522754B2 (ja) * 1993-12-16 2004-04-26 マリンクロッド・インコーポレイテッド 多価フェノール化合物類
US5998401A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
GB9707013D0 (en) * 1997-04-07 1997-05-28 Univ Strathclyde Halo and/or nitro-substituted flavonoids
JP2001523258A (ja) * 1997-05-01 2001-11-20 ノボゲン インコーポレイテッド 更年期症状および骨粗鬆症の治療または予防

Also Published As

Publication number Publication date
NO20015015D0 (no) 2001-10-15
PL351314A1 (en) 2003-04-07
WO2000062765A2 (en) 2000-10-26
US6518301B1 (en) 2003-02-11
CZ20013714A3 (cs) 2002-08-14
HUP0200740A3 (en) 2004-08-30
HUP0200740A2 (hu) 2002-07-29
AR043085A1 (es) 2005-07-20
SK14762001A3 (sk) 2002-10-08
MXPA01010423A (es) 2002-03-27
CN1358091A (zh) 2002-07-10
KR20010108509A (ko) 2001-12-07
NO20015015L (no) 2001-12-17
EE200100526A (et) 2002-12-16
BG106103A (en) 2002-05-31
EP1173164A2 (en) 2002-01-23
AU4128800A (en) 2000-11-02
TR200201762T2 (tr) 2002-10-21
WO2000062765A3 (en) 2001-09-07
ZA200108409B (en) 2003-03-26
TR200102992T2 (tr) 2004-12-21
JP2002542187A (ja) 2002-12-10
CA2370126A1 (en) 2000-10-26
IS6108A (is) 2001-10-15
IL145839A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
BR0009814A (pt) Processo para tratar de uma doença associada com o receptor-beta estrogênico
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
BR9903984B1 (pt) processo para a produção de uma composição aquosa que contém um peptìdeo farmaceuticamente efetivo.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
BRPI0111116B8 (pt) imitadores de trombopoietina
UY26130A1 (es) Compuestos para tratar la obesidad
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
BR9913457A (pt) Neuroproteção
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
BR0215258A (pt) Moduladores de receptor x de fìgado de tioéter aromático
PE20011131A1 (es) Compuestos tetraciclicos no esteroides para tratamientos relacionados con estrogenos
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
BR9911559A (pt) Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo.
NO20005981D0 (no) Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- &lt;kappa&gt;B
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
BR0109789A (pt) Método para o tratamento de câncer de mama, e, uso de fulvestrante

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.